A Phase 1, Single Center, Double-blind, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Effects of Single Oral Doses of AEF0117 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
Price : $35 *
At a glance
- Drugs AEF 0117 (Primary)
- Indications Substance-related disorders
- Focus Adverse reactions
- Sponsors Aelis Farma
- 12 Mar 2018 Status changed from recruiting to completed.
- 15 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 15 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.